<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04554875</url>
  </required_header>
  <id_info>
    <org_study_id>20200410</org_study_id>
    <nct_id>NCT04554875</nct_id>
  </id_info>
  <brief_title>Derivation and Validation of a Scoring System to Distinguish Cryptococcosis and Adenocarcinoma in Pulmonary Nodules</brief_title>
  <official_title>Derivation and Validation of a Scoring System to Distinguish Cryptococcosis and Adenocarcinoma in Pulmonary Nodules: a Multicenter Observational Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Pulmonary Hospital, Shanghai, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Pulmonary Hospital, Shanghai, China</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pulmonary cryptococcosis often manifests as isolated or multiple nodules, easily mimicking&#xD;
      lung cancer clinically and radiologically, which ascribes the poor sensitivity of&#xD;
      Cryptococcus culture and rarely positive of Cryptococcal antigen test in the absence of&#xD;
      disseminated disease. Therefore, the aim of this study was to develop a predictive scoring&#xD;
      system from the perspective of available clinical indicators, to differentiate cryptococcosis&#xD;
      from adenocarcinoma in pulmonary nodules, which might be beneficial for the delicacy&#xD;
      management of pulmonary nodules.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nodule is generally defined as a small, approximately spherical in morphology, circumscribed&#xD;
      focus of abnormal tissue on computed tomography (CT) and no greater than 3cm in maximum&#xD;
      diameter. Pulmonary nodules are not uncommon. A systematic review of CT screening lung cancer&#xD;
      trials noted that a lung nodule was detected in up to 51% of study participants. More than&#xD;
      95% of detected nodules are benign and have a wide variety of causes, including infections,&#xD;
      granulomatous disease, hamartomas, arteriovenous malformations, round atelectasis, and lymph&#xD;
      nodes.&#xD;
&#xD;
      Pulmonary cryptococcosis is caused by Cryptococcus spp., a ubiquitous budding yeast-like&#xD;
      basidiomycete that is endemic in many countries. Previously, Pulmonary cryptococcosis was&#xD;
      thought to be an important opportunistic invasive mycosis in immunocompromised patients, such&#xD;
      as AIDS, immunosuppressor used after organ transplantation, but it is also common in&#xD;
      immunocompetent patients. Pulmonary cryptococcosis often manifests as isolated or multiple&#xD;
      nodules, easily mimicking lung cancer clinically and radiologically, which ascribes the poor&#xD;
      sensitivity of Cryptococcus culture and rarely positive of Cryptococcal antigen test in the&#xD;
      absence of disseminated disease.&#xD;
&#xD;
      Therefore, the aim of this multicenter observational study was to develop a predictive&#xD;
      scoring system from the perspective of available clinical indicators, to differentiate&#xD;
      cryptococcosis from adenocarcinoma in pulmonary nodules, which might be beneficial for the&#xD;
      delicacy management of pulmonary nodules.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">July 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Area under receiver operating characteristic curve</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Area under Receiver Operating Characteristic (ROC) curve was used to identify the diagnostic value of the scoring system.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity of the scoring system</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Sensitivity of the scoring system was used to assess the true positive rate of pulmonary cryptococcosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specificity of the scoring system</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Specificity of the scoring system was used to assess the true negative rate of pulmonary cryptococcosis</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Cryptococcosis</condition>
  <condition>Lung Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <description>Derivation Cohort of a Scoring System to Distinguish Cryptococcosis and Adenocarcinoma in Pulmonary Nodules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <description>One of Validation Cohorts of a Scoring System to Distinguish Cryptococcosis and Adenocarcinoma in Pulmonary Nodules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <description>One of Validation Cohorts of a Scoring System to Distinguish Cryptococcosis and Adenocarcinoma in Pulmonary Nodules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <description>One of Validation Cohorts of a Scoring System to Distinguish Cryptococcosis and Adenocarcinoma in Pulmonary Nodules</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>A scoring system</intervention_name>
    <description>The scoring system was used to rate score patients.</description>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with pulmonary nodules, no greater than 3cm in maximum diameter, finally diagnosed&#xD;
        with cryptococcosis or adenocarcinoma were included in this study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with pulmonary nodules&#xD;
&#xD;
          -  Evidence of pathological diagnosis for cryptococcosis or adenocarcinoma&#xD;
&#xD;
          -  Data on high-resolution computed tomography (HRCT)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pulmonary nodules greater than 3cm in maximum diameter&#xD;
&#xD;
          -  Lack of data on HRCT&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Jin-fu Xu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Pulmonary Hospital, Shanghai, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jin-fu Xu, MD</last_name>
    <phone>+86 13321922898</phone>
    <email>jfxucn@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai pulmonary hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin-fu Xu, MD</last_name>
      <phone>+8613321922898</phone>
      <email>jfxucn@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 11, 2020</study_first_submitted>
  <study_first_submitted_qc>September 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2020</study_first_posted>
  <last_update_submitted>September 17, 2020</last_update_submitted>
  <last_update_submitted_qc>September 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Pulmonary Hospital, Shanghai, China</investigator_affiliation>
    <investigator_full_name>Jin-Fu Xu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cryptococcosis</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Adenocarcinoma of Lung</mesh_term>
    <mesh_term>Multiple Pulmonary Nodules</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

